Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Caroline Gjestad"'
Publikováno v:
British Journal of Clinical Pharmacology. 83:2398-2405
SummaryAim 4β-Hydroxycholesterol (4βOHC) is sensitive towards induction or inhibition of CYP3A4, but its potential usefulness as a dosing biomarker remains to be demonstrated. The aim of this study was to investigate the correlation between 4βOHC
Autor:
Caroline Gjestad, Birgit M Wollmann, Lise Larsen Mehus, IC Olsen, Espen Molden, E Lie, SW Syversen
Publikováno v:
Clinical and Translational Science. 10:42-49
Systemic inflammation has been linked to suppressed CYP3A(4) activity. We determined 4β-hydroxycholesterol (4βOHC), an endogenous CYP3A4 metabolite, in patients with rheumatoid arthritis (RA) before and after treatment with biological disease-modif
Publikováno v:
British Journal of Clinical Pharmacology. 81:269-276
AIM 4β-hydroxycholesterol (4βOHC) is an endogenous CYP3A(4) biomarker, which is elevated by use of the CYP3A4 inducer carbamazepine. Our aim was to compare to what extent serum concentration of 4βOHC correlates with dose (presystemic exposure) and
Autor:
Caroline Gjestad, Petra Lybæk Heiberg, Øyvind Rø, Lise Larsen Mehus, Espen Molden, Kristine Hole
Publikováno v:
Pharmacology Research & Perspectives
Recent studies have shown that the cytochrome P450 (CYP) 3A phenotype marker 4β‐hydroxycholesterol/cholesterol (4βOHC/C) ratio is negatively correlated with body weight in healthy volunteers, and that obese patients have lower 4βOHC levels than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4229442a04727a1f3a7ac2e278fe55a1
http://hdl.handle.net/10852/72614
http://hdl.handle.net/10852/72614
Publikováno v:
Therapeutic Drug Monitoring
Background: The selective serotonin reuptake inhibitors (SSRIs) citalopram, escitalopram, and sertraline are all metabolized by the cytochrome P-450 isoenzyme CYP2C19, which is inhibited by the proton pump inhibitors (PPIs) omeprazole, esomeprazole,
4β-Hydroxycholesterol (4βOHC) is sensitive towards induction or inhibition of CYP3A4, but its potential usefulness as a dosing biomarker remains to be demonstrated. The aim of this study was to investigate the correlation between 4βOHC levels and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::600d377013fb8c2ab045f259e652f21f
https://europepmc.org/articles/PMC5651320/
https://europepmc.org/articles/PMC5651320/
Publikováno v:
British Journal of Clinical Pharmacology. 84:1624-1625
Publikováno v:
European journal of clinical pharmacology. 73(3)
Individual variability in the endogenous CYP3A metabolite 4β-hydroxycholesterol (4βOHC) is substantial, but to which extent this is determined by genetic and nongenetic factors remains unclear. The aim of the study was to evaluate the explanatory p
Publikováno v:
British journal of clinical pharmacology. 81(2)
4β-hydroxycholesterol (4βOHC) is an endogenous CYP3A(4) biomarker, which is elevated by use of the CYP3A4 inducer carbamazepine. Our aim was to compare to what extent serum concentration of 4βOHC correlates with dose (presystemic exposure) and ste